Dashboard
Manage Tickers

BIIBBIOGEN INC.

Nasdaq biogen.com


$ 219.94 $ -3.64 (-1.63 %)    

Thursday, 23-May-2024 11:57:09 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -1.82 (-0.39 %)
DIA $ 398.57 $ -2.75 (-0.69 %)
SPY $ 530.36 $ -1.63 (-0.31 %)
TLT $ 91.26 $ -0.82 (-0.89 %)
GLD $ 225.37 $ -2.04 (-0.93 %)
$ 225.21
$ 223.58
$ 0.00 x 0
$ 0.00 x 0
$ 217.22 - $ 223.58
$ 189.44 - $ 319.76
1,225,658
na
32.86B
$ 0.69
$ 28.17
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-24-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 07-25-2023 06-30-2023 10-Q
5 04-25-2023 03-31-2023 10-Q
6 02-15-2023 12-31-2022 10-K
7 10-25-2022 09-30-2022 10-Q
8 07-20-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 02-03-2022 12-31-2021 10-K
11 10-20-2021 09-30-2021 10-Q
12 07-22-2021 06-30-2021 10-Q
13 04-22-2021 03-31-2021 10-Q
14 02-03-2021 12-31-2020 10-K
15 10-21-2020 09-30-2020 10-Q
16 07-22-2020 06-30-2020 10-Q
17 04-23-2020 03-31-2020 10-Q
18 02-06-2020 12-31-2019 10-K
19 10-22-2019 09-30-2019 10-Q
20 07-24-2019 06-30-2019 10-Q
21 04-24-2019 03-31-2019 10-Q
22 02-06-2019 12-31-2018 10-K
23 10-23-2018 09-30-2018 10-Q
24 07-24-2018 06-30-2018 10-Q
25 04-24-2018 03-31-2018 10-Q
26 02-01-2018 12-31-2017 10-K
27 10-24-2017 09-30-2017 10-Q
28 07-25-2017 06-30-2017 10-Q
29 04-25-2017 03-31-2017 10-Q
30 02-02-2017 12-31-2016 10-K
31 10-26-2016 09-30-2016 10-Q
32 07-21-2016 06-30-2016 10-Q
33 04-21-2016 03-31-2016 10-Q
34 02-03-2016 12-31-2015 10-K
35 10-21-2015 09-30-2015 10-Q
36 07-24-2015 06-30-2015 10-Q
37 04-24-2015 03-31-2015 10-Q
38 02-04-2015 12-31-2014 10-K
39 10-22-2014 09-30-2014 10-Q
40 07-23-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-biogen-maintains-300-price-target
HC Wainwright & Co. Reiterates Buy on Biog...
05/23/2024 10:10:49

HC Wainwright & Co. analyst Andrew Fein reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $300 price target.

deep-dive-into-biogen-stock-analyst-perspectives-17-ratings
Deep Dive Into Biogen Stock: Analyst Persp...
05/22/2024 14:00:23

needham-reiterates-buy-on-biogen-maintains-294-price-target
Needham Reiterates Buy on Biogen, Maintain...
05/22/2024 13:37:39

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.

biogen-has-agreed-to-acquire-human-immunology-biosciences-for-115b-upfront-and-up-to-650m-in-potential-milestone-payments
Biogen Has Agreed To Acquire Human Immunol...
05/22/2024 11:32:13

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product ...

larimar-therapeutics-friedreichs-ataxia-investigational-drug-differentiated-from-biogens-marketed-drug
Larimar Therapeutics' Friedreich's Ataxia ...
05/21/2024 18:39:04

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data fr...

how-is-the-market-feeling-about-biogen
How Is The Market Feeling About Biogen?
05/20/2024 20:45:13

truist-securities-maintains-buy-on-biogen-maintains-340-price-target
Truist Securities Maintains Buy on Biogen,...
05/16/2024 17:14:29

Truist Securities analyst Robyn Karnauskas maintains Biogen (NASDAQ:BIIB) with a Buy and maintains $340 price target.

tale-of-two-ionis-partnered-neurology-focused-early-stage-assets-biogen-discontinues-one-decides-not-to-exercise-licensing-option-for-another
Tale Of Two Ionis-Partnered Neurology-Focu...
05/16/2024 16:11:55

Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on k...

Core News & Articles
Ionis And Biogen Say Development Of BIIB10...
05/16/2024 11:36:34

Core News & Articles
Reported Earlier, Biogen And Eisai Initiat...
05/15/2024 06:51:14

LEQEMBI is now approved in the U.S., Japan and China, and applications have been submitted for review in the European Union, Au...

jim-cramer-likes-micron-and-its-ceo-recommends-buying-this-big-bank
Jim Cramer Likes Micron And Its CEO, Recom...
05/13/2024 13:15:02

Jim Cramer recommends buying Micron, adding that he likes the company's CEO Sanjay Mehrotra. As for Fidelis? "Not a fav...

hsbc-maintains-buy-on-biogen-raises-price-target-to-342
HSBC Maintains Buy on Biogen, Raises Price...
05/03/2024 18:41:12

HSBC analyst Morten Herholdt maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $339 to $342.

the-analyst-landscape-27-takes-on-biogen
The Analyst Landscape: 27 Takes On Biogen
04/29/2024 17:01:07

oppenheimer-maintains-outperform-on-biogen-maintains-270-price-target
Oppenheimer Maintains Outperform on Biogen...
04/29/2024 16:49:51

Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and maintains $270 price target.

will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports-this-week
Will Earnings Cheer Continue To Buoy Marke...
04/29/2024 05:51:21

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...

barclays-maintains-equal-weight-on-biogen-lowers-price-target-to-200
Barclays Maintains Equal-Weight on Biogen,...
04/25/2024 18:02:40

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $215 to $200.

these-analysts-revise-their-forecasts-on-biogen-after-q1-results
These Analysts Revise Their Forecasts On B...
04/25/2024 12:53:14

meta-platforms-to-rally-around-14-here-are-10-top-analyst-forecasts-for-thursday
Meta Platforms To Rally Around 14%? Here A...
04/25/2024 12:44:41

wedbush-maintains-neutral-on-biogen-raises-price-target-to-215
Wedbush Maintains Neutral on Biogen, Raise...
04/25/2024 12:33:01

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $213 to $215.

hc-wainwright--co-maintains-buy-on-biogen-lowers-price-target-to-300
HC Wainwright & Co. Maintains Buy on Bioge...
04/25/2024 11:53:17

HC Wainwright & Co. analyst Andrew Fein maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $325 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION